{
  "items": [
    {
      "title": "What Moved Markets This Week",
      "description": "U.S. stocks end a tough week as DeepSeek rattles tech stocks and the Fed Holds interest rates steady. Read more about this week's major events on Wall Street.",
      "published_utc": "2025-02-01T14:38:48",
      "source": "SeekingAlpha",
      "url": "https://finnhub.io/api/news?id=d4c5af02929f10b7ead3e6e81da69934cd05a6efeb931ba87d28f5c1e6bafd2a",
      "category": "company",
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1483074556/image_1483074556.jpg?io=getty-c-w1536",
      "related_symbols": [
        "JNJ"
      ],
      "api_source": "finnhub_company",
      "id": 132509831,
      "datetime": 1738391928
    },
    {
      "id": "1fe9bf294c8e0eaee389d9424796a3f0c749aa7101d3e736632bf55c7b2f0fa8",
      "publisher": {
        "name": "The Motley Fool",
        "homepage_url": "https://www.fool.com/",
        "logo_url": "https://s3.polygon.io/public/assets/news/logos/themotleyfool.svg",
        "favicon_url": "https://s3.polygon.io/public/assets/news/favicons/themotleyfool.ico"
      },
      "title": "Johnson & Johnson Announces a Major Acquisition. Can It Turn the Stock's Fortunes Around?",
      "author": "The Motley Fool",
      "published_utc": "2025-02-01T12:30:00Z",
      "article_url": "https://www.fool.com/investing/2025/02/01/johnson-johnson-announces-a-major-acquisition-can/?source=iedfolrf0000001",
      "tickers": [
        "JNJ",
        "ITCI",
        "XLV"
      ],
      "image_url": "https://g.foolcdn.com/editorial/images/805120/doctor-meeting-a-salesperson.jpg",
      "description": "Johnson & Johnson announced plans to acquire Intra-Cellular Therapies for $14.6 billion, which could bolster its pipeline and strengthen its neurological business. However, the acquisition is unlikely to turn Johnson & Johnson into a high-growth stock, as its growth rate is expected to remain in the single digits.",
      "keywords": [
        "Johnson & Johnson",
        "Intra-Cellular Therapies",
        "acquisition",
        "growth",
        "neurological business"
      ],
      "insights": [
        {
          "ticker": "JNJ",
          "sentiment": "neutral",
          "sentiment_reasoning": "The article suggests that the acquisition of Intra-Cellular Therapies could help diversify Johnson & Johnson's business and contribute to its long-term growth, but it is unlikely to turn the company into a high-growth stock. The article also notes that Johnson & Johnson's talc lawsuits are still unresolved, which creates some risk and uncertainty surrounding the business."
        },
        {
          "ticker": "ITCI",
          "sentiment": "positive",
          "sentiment_reasoning": "The article highlights that Intra-Cellular Therapies has a key product, Caplyta, which is an approved treatment for schizophrenia and depression and could generate over $5 billion in peak sales. The acquisition of Intra-Cellular Therapies is seen as a good way for Johnson & Johnson to bolster its pipeline and strengthen its neurological business."
        },
        {
          "ticker": "XLV",
          "sentiment": "neutral",
          "sentiment_reasoning": "The article compares Johnson & Johnson's forward P/E ratio to the average forward P/E of the Health Care Select Sector SPDR Fund, which is higher, suggesting that Johnson & Johnson may be a relatively cheaper investment option."
        }
      ]
    },
    {
      "id": "7c5236bd57cebc010a52ad7905be0cd3c61c33c63977ee4662a9f431f2b7bf47",
      "publisher": {
        "name": "The Motley Fool",
        "homepage_url": "https://www.fool.com/",
        "logo_url": "https://s3.polygon.io/public/assets/news/logos/themotleyfool.svg",
        "favicon_url": "https://s3.polygon.io/public/assets/news/favicons/themotleyfool.ico"
      },
      "title": "Did Johnson & Johnson Just Give Investors 23 Billion Reasons to Buy Its Stock?",
      "author": "Eric Volkman",
      "published_utc": "2025-02-01T11:14:00Z",
      "article_url": "https://www.fool.com/investing/2025/02/01/did-johnson-johnson-just-give-investors-23-billion/?source=iedfolrf0000001",
      "tickers": [
        "JNJ",
        "KVUE"
      ],
      "image_url": "https://g.foolcdn.com/editorial/images/805493/child-receiving-a-vaccination-shot-from-a-healthcare-professional.jpg",
      "description": "Johnson & Johnson reported strong Q4 2024 earnings, with top-line growth and a double beat on analyst estimates. The company's outlook for 2025 is also positive, with guidance for improved profitability and continued dividend growth. The article suggests that Johnson & Johnson's stock is a buy due to its growth potential and reliable income stream.",
      "keywords": [
        "Johnson & Johnson",
        "earnings",
        "outlook",
        "dividend",
        "stock recommendation"
      ],
      "insights": [
        {
          "ticker": "JNJ",
          "sentiment": "positive",
          "sentiment_reasoning": "The article highlights Johnson & Johnson's strong Q4 2024 earnings, with top-line growth, a double beat on analyst estimates, and a positive outlook for 2025 with improved profitability and continued dividend growth. The article suggests the stock is a buy due to its growth potential and reliable income stream."
        },
        {
          "ticker": "KVUE",
          "sentiment": "neutral",
          "sentiment_reasoning": "The article mentions that Johnson & Johnson hived off its consumer healthcare products business as the separately managed and traded Kenvue in mid-2023, but does not provide any further details or sentiment on Kenvue."
        }
      ]
    }
  ]
}